Category:Empathogens: Difference between revisions

Line 1:

This category groups ~~medicines belonging to~~ the [[~~Classes~~|~~Empathogens / Entactogens~~]] class. ~~See~~ [[~~Classes~~]] for the ~~full taxonomy~~.

The '''empathogens''', also called entactogens, are the psychoactive materials that produce a particular state of emotional openness: a softening of fear and defensiveness, a feeling of warmth and trust, and a heightened sense of closeness to other people. They share an ancestry with the [[:Category:Psychedelics|psychedelics]] proper but are set apart from them by what they largely do not do, for at ordinary doses they bring little of the visual and perceptual change that marks [[LSD]] or [[psilocybin]]. The class is built around a single material, [[MDMA]], and its story is for the most part MDMA's: a substance first made and shelved by a pharmaceutical company, taken up half a century later as an aid to psychotherapy, driven from the clinic into prohibition and onto the dance floor as "Ecstasy," and now, slowly and against considerable resistance, being escorted back toward the clinic. It is, as well, a class that for years could not agree on its own name.

== The methylenedioxy lineage ==

The oldest material in the class is [[MDA]], 3,4-methylenedioxyamphetamine, first prepared in 1910 by the chemists Carl Mannich and Willy Jacobsohn.<ref name="pentney">Pentney AR. An exploration of the history and controversies surrounding MDMA and MDA. ''Journal of Psychoactive Drugs.'' 2001;33(3):213-221. PMID: 11718314. DOI: 10.1080/02791072.2001.10400568.</ref> It drew little notice until 1930, when it was swallowed, in a dose of about 126 milligrams, by the American chemist Gordon Alles, who had earlier established the stimulant properties of amphetamine; Alles recorded euphoria, a sense of well-being, and mild perceptual effects, though he did not publish the account for almost three decades. In the 1950s the firm Smith, Kline and French gave MDA to several hundred volunteers in trials of its possible use as an antidepressant and as an appetite suppressant. By the late 1960s it had reached the street, where its capacity to soften feeling and to heighten the sense of connection earned it the nickname "the love drug." In 1970 the United States Controlled Substances Act placed MDA in Schedule I.

[[MDMA]], 3,4-methylenedioxymethamphetamine, the material that would come to define the class, was made earlier still. It was first synthesized in 1912 by the chemist Anton Köllisch at the German pharmaceutical company Merck, under the name Methylsafrylamin. A persistent account, repeated for decades in the medical literature, holds that Merck developed MDMA as an appetite suppressant. Archival research has shown this to be a myth. A reconstruction from Merck's own original documents found that MDMA was never an object of the company's research at all, but an incidental intermediate in a new synthetic route toward a styptic, an agent used to stop bleeding; the route was patented chiefly to work around a competitor's patent.<ref name="freudenmann">Freudenmann RW, Öxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. ''Addiction.'' 2006;101(9):1241-1245. PMID: 16911722. DOI: 10.1111/j.1360-0443.2006.01511.x.</ref> MDMA was set aside. Merck examined its pharmacology briefly in 1927 and again in 1959, but, so far as the surviving records show, never gave it to a human being. For some sixty years it remained, in effect, a forgotten line in a patent.

== Adam: the years of therapy ==

MDMA re-entered the world through the same prohibition that had removed MDA. When MDA was scheduled in 1970, MDMA, still uncontrolled, began to appear quietly in its place; it is recorded on the street in Chicago that year. Its true rediscovery, though, belongs to the American chemist Dr. Alexander "Sasha" Shulgin. Having heard of an unusual effect the compound produced, Dr. Shulgin re-synthesized MDMA and, in September 1976, took it himself; his laboratory notebook records the date.<ref name="benzenhofer">Benzenhöfer U, Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. ''Addiction.'' 2010;105(8):1355-1361. PMID: 20653618. DOI: 10.1111/j.1360-0443.2010.02948.x.</ref>

The good Dr. Shulgin, persuaded that the compound could serve as a tool for self-examination, passed it in 1977 to Leo Zeff, a psychologist in Oakland who used psychoactive materials as adjuncts to therapy. Zeff was sufficiently struck by MDMA that he came out of a semi-retirement to teach its use, traveling widely to introduce it to other therapists. He called it "Adam," a name meant to summon a state of primal innocence, of being unguarded. Through the late 1970s and the early 1980s several thousand people are thought to have received MDMA in therapeutic settings, where it was valued for its capacity to lower fear and defensiveness and to let a patient revisit painful experience without being overwhelmed by it. All of this took place while the material was entirely legal.

It was in these years that the class acquired its names, and its disagreement over them. Around 1983 and 1984 the term "empathogen," meaning roughly "generating empathy," was proposed independently by the psychologist Ralph Metzner and the pharmacologist David Nichols. Nichols soon set the word aside, uneasy that its Greek root, pathos, carrying the sense of suffering, might invite the wrong association, and judging in any case that the term named only one part of what the materials did. In 1986 he proposed instead "entactogen," from roots meaning approximately "to touch within," and argued in print that MDMA and its close relatives formed a pharmacological class distinct from the classic hallucinogens.<ref name="nichols1986">Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. ''Journal of Psychoactive Drugs.'' 1986;18(4):305-313. PMID: 2880944. DOI: 10.1080/02791072.1986.10472362.</ref> Both terms remain in use, and the disagreement between them has never entirely closed.

== Ecstasy and prohibition ==

MDMA's second life, as a material of the dance floor, began with a change of name. In 1981 a distributor named Michael Clegg chose the word "Ecstasy" as a sales term; "empathy" would have been the more accurate choice, he is reported to have said, but "ecstasy" would sell better. Clegg's organization, later known as the Texas Group, mass-produced MDMA and from 1983 marketed it openly in the bars and discotheques of Dallas, complete with toll-free telephone numbers and advertised "Ecstasy parties." For a few years MDMA was a legal, branded, and briskly traded intoxicant.<ref name="mdma_wiki">MDMA. Wikipedia. Available at https://en.wikipedia.org/wiki/MDMA (accessed 22 May 2026).</ref>

That openness hastened its prohibition. On 1 July 1985 the United States Drug Enforcement Administration used its emergency powers to place MDMA in Schedule I, the most restrictive class, on a temporary basis. Hearings followed, at which clinicians and researchers testified to the material's use in therapy, and in 1986 the agency's own administrative law judge, Francis Young, recommended that MDMA be placed in the less restrictive Schedule III, having found that it possessed an accepted medical use. The agency's administrator overruled the recommendation, and on 22 February 1988 MDMA was placed permanently in Schedule I, where it has remained.<ref name="scheduling">Temporary placement of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I, 50 Fed. Reg. 23118 (31 May 1985), effective 1 July 1985. Permanent placement of MDMA into Schedule I, 53 Fed. Reg. 5156 (22 February 1988), effective 23 March 1988. In 1986, DEA Administrative Law Judge Francis L. Young, after hearings, recommended Schedule III placement on a finding of accepted medical use; the recommendation was not adopted by the DEA Administrator.</ref>

Prohibition did not check MDMA's spread; it changed its setting. From about 1985 the material became bound up with the acid-house music of the Spanish island of Ibiza, and from there it traveled with rave culture into Britain and then across Europe and North America. By the 1990s "Ecstasy" was among the defining intoxicants of a generation of dance music.

== The research-chemical wave ==

The prohibition of MDMA created a market for materials that resembled it but were not themselves yet controlled, and from the 1990s onward a long succession of these appeared, sold sometimes as substitutes for MDMA and sometimes, deceptively, as MDMA itself. A number are now indexed in this category.

One line of descent ran through the cathinones, the chemical family of [[cathinone]], the stimulant of the [[khat]] shrub. [[Methylone]], the cathinone counterpart of MDMA, was among the first to reach the market, reported in Europe in 2005; [[Ethylone]] and [[Butylone]] followed, and the closely related [[Mephedrone]] spread very rapidly between about 2007 and 2010 to become, for a time, one of the most widely used of the new materials.<ref name="euda_cathinones">Synthetic cathinones drug profile. European Union Drugs Agency (EUDA), formerly the European Monitoring Centre for Drugs and Drug Addiction. Available at https://www.euda.europa.eu/publications/drug-profiles/synthetic-cathinones_en (accessed 22 May 2026).</ref> Another line ran through the [[:Category:Benzofurans|benzofurans]], among them [[5-APB]] and [[6-APB]], sold under names such as "Benzo Fury," in which a benzofuran ring stands in for the methylenedioxy ring of MDMA; [[5-MAPB]] and [[6-APDB]] belong to the same group. [[4-FA]], a fluorinated amphetamine of empathogenic character, found a particular following in the Netherlands.

The wave produced its casualties. [[PMA]] and [[PMMA]], the para-methoxyamphetamines, take effect slowly, which can lead a person expecting the quicker onset of MDMA to take a second dose before the first is felt; the consequence is a dangerous, sometimes fatal overheating, and both materials have been implicated in clusters of deaths among people who believed they had taken MDMA.<ref name="pmma">European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs. EMCDDA Risk Assessments No. 5. Lisbon: EMCDDA; 2003. ISBN 92-9168-137-7. Available at https://www.euda.europa.eu/system/files/media/publications/documents/288/Risk5_62949.pdf (accessed 22 May 2026).</ref> [[MCPP]], a piperazine, has been among the substances most often found in tablets sold as "Ecstasy" that contain no MDMA at all. It was against this background that [[MDAI]], a rigid relative of MDA designed in a research laboratory, drew interest as a possible empathogen lacking the toxic effects of which MDMA was suspected.

== The neurotoxicity question ==

Whether MDMA inflicts lasting injury on the brain has been disputed for almost as long as it has been studied, and the dispute is not closed. Animal research has shown, with some consistency, that high or repeated doses of MDMA can damage the fine nerve terminals that release serotonin, producing long-lasting reductions in the chemical markers of serotonin function. Whether the same occurs in people who use MDMA recreationally, and at what dose it might begin, is far less clear: the human studies are confounded by the use of other materials alongside MDMA, by uncertainty about the doses actually taken, and by the difficulty of examining a living brain directly.

The controversy produced one cautionary episode that is still cited. In 2002 a group led by George Ricaurte published, in the journal ''Science'', a study reporting that doses of MDMA comparable to recreational use had caused severe damage to dopamine-releasing neurons in primates, two of which had died, a finding that implied a risk of parkinsonism in users of the material.<ref name="ricaurte2002">Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). ''Science.'' 2002;297(5590):2260-2263. PMID: 12351788. DOI: 10.1126/science.1074501. This article was retracted in 2003.</ref> The result could not be reproduced, by other laboratories or by the authors themselves, and in 2003 the paper was retracted: the animals, it emerged, had been given not MDMA but [[methamphetamine]], the two compounds having reached the laboratory in mislabeled bottles.<ref name="ricaurte_retraction">Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Retraction. ''Science.'' 2003;301(5639):1479. PMID: 12970544. DOI: 10.1126/science.301.5639.1479b.</ref> The episode is often invoked as a lesson in how far a striking result can outrun its evidence. It did not, however, resolve the underlying question, which remains open.

== The return to the clinic ==

The effort to return MDMA to medicine has been carried, for nearly four decades, chiefly by a single organization: the Multidisciplinary Association for Psychedelic Studies, founded in 1986, the year of MDMA's permanent prohibition, by Rick Doblin. Its method was the patient one of formal clinical research. From the 2000s onward the association sponsored trials of MDMA-assisted therapy for post-traumatic stress disorder, a treatment in which the material is given on a small number of occasions within a longer course of psychotherapy, rather than taken continuously in the manner of a conventional medicine.

Two phase 3 trials, reported in 2021 and 2023, found that MDMA-assisted therapy produced a greater reduction in the symptoms of post-traumatic stress disorder than the same psychotherapy accompanied by a placebo.<ref name="mitchell2021">Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. ''Nature Medicine.'' 2021;27(6):1025-1033. PMID: 33972795. DOI: 10.1038/s41591-021-01336-3.</ref><ref name="mitchell2023">Mitchell JM, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. ''Nature Medicine.'' 2023;29(10):2473-2480. PMID: 37709999. DOI: 10.1038/s41591-023-02565-4.</ref> On the strength of these results the trials' sponsor, by then the public-benefit company Lykos Therapeutics, applied to the United States Food and Drug Administration for approval. The application did not succeed. An advisory committee to the agency, meeting in June 2024, voted that the evidence had not established the treatment as effective, and raised concerns about the conduct of the trials, among them the near-impossibility of keeping participants and therapists unaware of who had received MDMA, and allegations of misconduct during the studies. In August 2024 the agency declined to approve the treatment and asked for a further phase 3 study.<ref name="fda2024">United States Food and Drug Administration. Complete Response Letter to Lykos Therapeutics concerning MDMA-assisted therapy for post-traumatic stress disorder. Issued August 2024; publicly released by the FDA on 4 September 2025.</ref> As of 2026, MDMA-assisted therapy is not an approved treatment in the United States, and whether MDMA will complete its passage back to the clinic is, once again, an open question.

== Mechanisms ==

The empathogens are understood to act chiefly as releasers of the brain's monoamine neurotransmitters. Where a classic psychedelic such as [[LSD]] is thought to work mainly by stimulating a particular serotonin receptor, the 5-HT2A receptor, an empathogen instead enters the nerve terminal by way of the monoamine transporters and causes serotonin, and to a lesser extent dopamine and norepinephrine, to be released into the synapse. The strong release of serotonin in particular is the action most often connected with the warmth and the sociability that give the class its name; and the distinction between this releasing action and the receptor-stimulating action of the psychedelics was central to the argument, set out by Nichols, that the entactogens were a class of their own.<ref name="nichols1986"/> That the empathogens release serotonin in this manner is well established; the fuller relationship between that release and the range of emotional and social effects the materials produce is more complex, and remains a subject of research.

== Safety ==

The acute dangers of the empathogens are, in large part, the dangers of MDMA, and the most characteristic of them is overheating. MDMA raises body temperature, an effect that can be compounded by a hot and crowded setting and by sustained physical exertion; severe hyperthermia is a recognized mechanism of serious harm and of death. A second and in a sense opposite danger arises from the response to the first: drinking large amounts of water without replacing salt can produce a dangerous dilution of the blood's sodium, a hyponatremia that has also caused deaths. Taken together with another serotonergic material, an empathogen can contribute to the serotonin syndrome, a state of dangerous overactivity. The adulteration of the illicit "Ecstasy" supply adds a further hazard, since a tablet sold as MDMA may instead contain more dangerous materials, the para-methoxyamphetamines among them, or none of the expected material at all. The longer-term question of serotonergic injury is discussed above. Figures for these risks are population estimates that vary between studies, and individual response varies considerably from person to person.

== Empathogens indexed ==

This category collects the wiki's empathogen pages, which fall into several structural groups.

* The methylenedioxy core of the class: [[MDMA]]; [[MDA]], its older relative; [[MDEA]]; and [[MDAI]], a rigid analogue of MDA. These also carry the [[:Category:MDxx|MDxx]] subcategory.

* The empathogenic cathinones, cathinones of methylenedioxy or related structure that carry an empathogen character: [[Methylone]], [[Ethylone]], [[Butylone]], and [[Mephedrone]].

* The benzofurans, in which a benzofuran ring replaces the methylenedioxy ring: [[5-APB]], [[6-APB]], [[5-MAPB]], and [[6-APDB]]. These also carry the [[:Category:Benzofurans|Benzofurans]] subcategory.

* Other materials encountered in the "Ecstasy" market: [[4-FA]], a fluorinated amphetamine; [[PMA]] and [[PMMA]], the para-methoxyamphetamines implicated in deaths; and [[MCPP]], a piperazine common in adulterated tablets.

== Notes on scope ==

This category indexes the empathogens: the materials whose defining effect is the empathogen, or entactogen, state, as distinct from the perceptual action of the classic [[:Category:Psychedelics|psychedelics]]. The boundary is that effect, and not any one chemical family; the members include substituted amphetamines, cathinones, benzofurans, and a piperazine.

The class overlaps others, and its members are cross-indexed accordingly. Many empathogens are also stimulants, and the line between an empathogen and a [[:Category:Psychostimulants|psychostimulant]] is one of degree rather than of kind; the cathinones in particular belong to both classes. Following the wiki's multi-membership convention, a material is indexed wherever its pharmacology warrants. Three materials are indexed here less for an empathogen effect of their own than because they belong to the empathogen story a reader needs: PMA and PMMA, which are sold as MDMA but act differently and far more dangerously, and MCPP, a frequent adulterant of tablets sold as "Ecstasy."

== About these pages ==

Each empathogen indexed here has, or in time will have, its own page, built on the wiki's standard structure for a medicine: a history-first account, followed by pharmacology, indications where any exist, adverse effects, and interactions.

This is one of the wiki's MedCategory class-overview pages. It carries the [[:Category:MedCategory|MedCategory]] and [[:Category:MedCategoryFull|MedCategoryFull]] marker tags; the second suppresses the member list that MediaWiki would otherwise generate automatically, leaving the curated index above as the one the reader sees. The category sits within the [[:Category:Psychedelics|psychedelics]], in the broad sense in which the wiki uses that grouping, and within the [[:Category:Pharmaceutical|Pharmaceutical]] origin root, the empathogens proper being products of the laboratory rather than of traditional practice. The wiki files the class under "empathogens"; "entactogens," the term the pharmacologist who defined the class came to prefer, is equally correct, and the unsettled choice between the two is itself a piece of the class's history.

== References ==

[[Category:MedCategory]]

[[Category:MedCategoryFull]]

[[Category:Pharmaceutical]]

[[Category:Psychedelics]]

~~[[Category:Pharmaceutical]]~~

MDElliottMD (talk | contribs)